Related Experiment Video
Updated: Jun 27, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Tiagabine: efficacy and safety in partial seizures - current status
Jürgen Bauer1, Déirdre Cooper-Mahkorn
1Department of Epileptology, Bonn University Hospital Germany.
Neuropsychiatric Disease and Treatment
|December 2, 2008
Summary
Tiagabine hydrochloride (TGB) is an antiepileptic drug effective for partial seizures. While beneficial, it carries risks like nonconvulsive status and requires careful dosing to avoid seizures or coma.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Tiagabine hydrochloride (TGB) is a selective gamma-aminobutyric acid (GABA) reuptake inhibitor.
- It is used as an add-on therapy for partial seizures in patients 12 years and older.
Purpose of the Study:
- To evaluate the efficacy and safety of tiagabine hydrochloride in epilepsy treatment.
- To assess its effectiveness as monotherapy and add-on treatment.
- To identify potential risks and side effects associated with TGB use.
Main Methods:
- Review of nonrandomized add-on trials.
- Comparison of TGB monotherapy with carbamazepine in newly diagnosed patients.
- Analysis of adverse events, including nonconvulsive status, side effects, and overdose risks.
Main Results:
- Seizure reduction of at least 50% was observed in 33% to 46% of patients in add-on trials.
- TGB monotherapy demonstrated comparable efficacy to carbamazepine in newly diagnosed partial epilepsy.
- Increased risk of nonconvulsive status epilepticus (7.8% vs 2.7%) and common side effects like dizziness and somnolence were noted.
- No adverse effects on cognition, fracture risk, or rash were reported.
- An intermediate risk for depression (approximately 4%) and potential interference with color perception were identified.
- Overdose incidents (96-680 mg) resulted in seizures or coma.
Conclusions:
- Tiagabine hydrochloride is an effective antiepileptic drug for partial seizures, particularly as add-on therapy.
- Its efficacy may be limited in comedication, and critical side effects like nonconvulsive status epilepticus necessitate cautious use.
- Careful monitoring and appropriate dosing are crucial to mitigate risks associated with TGB treatment.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...